Profile

TCGX is a healthcare investment firm with headquarters and offices in Palo Alto, San Francisco, and New York City. The firm was founded by Dr. Chen Yu, who has a vision to leverage scientific breakthroughs to develop new medicines. TCGX differentiates itself by focusing on biotechnology companies and bringing a robust global network to support entrepreneurs. With a dedicated team that includes Dandan Dong, the managing partner in Asia, TCGX aims to expand its footprint in the vibrant biotech sector of the region.

TCGX invests in biotechnology, with a focus on life sciences and Healthcare Services. The firm targets investments across all stages of development, from early-stage drug discovery to late-stage companies, primarily in the US, Europe, and expanding into Asia with their new fund. The check sizes are typically in the range of $10-50 m. They manage significant assets including their flagship funds in the US and Europe, and their newly launched Asia-focused fund with $600 million committed.

Some of the notable companies that TCGX has supported include life sciences startups in North America and Europe. While specific firms were not disclosed in the available details, the firm is recognized for partnering with innovative biotechnology companies that are led by entrepreneurs aiming to develop transformative medicines for global markets.

Industry

Life Sciences Healthcare Services Biotechnology

TCGX Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
TCGX Asia Life Sciences Fund I
Venture Capital (VC)
Biotechnology
Life Sciences
Pre-seed
Seed
Series A
Series B
Late Stage (Series C+)
Asia
$10-50 m
$600 M
October 2026

Contacts

Name
Title
Email
avatar
Cariad Chester Managing Partner
Managing Partner
c•••@•••
avatar
George Feng Senior Associate
Senior Associate
g•••@•••
Upgrade to see contacts
avatar
IXMnj9vGVeioOR6a IXMnj9vGVeioOR6a
IXMnj9vGVeioOR6a
avatar
IXMnj9vGVeioOR6a IXMnj9vGVeioOR6a
IXMnj9vGVeioOR6a
avatar
IXMnj9vGVeioOR6a IXMnj9vGVeioOR6a
IXMnj9vGVeioOR6a
Investment-team contacts for TCGX — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about TCGX

TCGX is a venture capital firm. It backs companies at Series A, Seed, Pre-seed, Late Stage (Series C+) and Series B, writing tickets of $10-50 m.
TCGX was founded in .
TCGX invests in companies and startups in Life Sciences, Healthcare Services, Biotechnology.
TCGX invests in companies and startups in Europe, North America, Asia.
TCGX invests in companies and startups at Series A, Seed, Pre-seed, Late Stage (Series C+), Series B.
TCGX usually invests $10-50 m on average.
TCGX last fund was created/launched in 2026-10-09
TCGX can be reached through its website tcgcrossover.com and its LinkedIn page. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for TCGX — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query TCGX directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 22 October, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.